Non Small Cell Lung Cancer

News alerts, weekly reports and conference planners

Related cancers:

‹

Lung Cancer (4035)

Lung Adenocarcinoma (638)

Lung Non-Squamous Non-Small Cell Cancer (147)

Lung Non-Small Cell Squamous Cancer (111)

Lung Cancer (4035)

Lung Adenocarcinoma (638)

Lung Non-Squamous Non-Small Cell Cancer (147)

Lung Non-Small Cell Squamous Cancer (111)

›

EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	atezolizumab Sensitive: A1 - Approval Anticancer Res - 4 days (New C3) atezolizumab Sensitive : A1 Anticancer Res - 4d	atezolizumab Sensitive: A1 - Approval Anticancer Res - 4 days atezolizumab Sensitive : A1 Anticancer Res - 4 days - (New C3)
BIRC5 overexpression	Non Small Cell Lung Cancer	BIRC5 overexpression	Non Small Cell Lung Cancer	carboplatin + paclitaxel Sensitive: C3 – Early Trials Asian Pac J Cancer Prev - 4 days (New C3) carboplatin + paclitaxel Sensitive : C3 Asian Pac J Cancer Prev - 4d	carboplatin + paclitaxel Sensitive: C3 – Early Trials Asian Pac J Cancer Prev - 4 days carboplatin + paclitaxel Sensitive : C3 Asian Pac J Cancer Prev - 4 days - (New C3)
RRM1 overexpression	Non Small Cell Lung Cancer	RRM1 overexpression	Non Small Cell Lung Cancer	carboplatin + paclitaxel Sensitive: C3 – Early Trials Asian Pac J Cancer Prev - 4 days (New C3) carboplatin + paclitaxel Sensitive : C3 Asian Pac J Cancer Prev - 4d	carboplatin + paclitaxel Sensitive: C3 – Early Trials Asian Pac J Cancer Prev - 4 days carboplatin + paclitaxel Sensitive : C3 Asian Pac J Cancer Prev - 4 days - (New C3)
TUBB3 underexpression	Non Small Cell Lung Cancer	TUBB3 underexpression	Non Small Cell Lung Cancer	carboplatin + paclitaxel Sensitive: C3 – Early Trials Asian Pac J Cancer Prev - 4 days (New C3) carboplatin + paclitaxel Sensitive : C3 Asian Pac J Cancer Prev - 4d	carboplatin + paclitaxel Sensitive: C3 – Early Trials Asian Pac J Cancer Prev - 4 days carboplatin + paclitaxel Sensitive : C3 Asian Pac J Cancer Prev - 4 days - (New C3)
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	amivantamab-vmjw + lazertinib Sensitive: B - Late Trials J&J Press Release - 5 days (New B) amivantamab-vmjw + lazertinib Sensitive : B J&J Press Release - 5d	amivantamab-vmjw + lazertinib Sensitive: B - Late Trials J&J Press Release - 5 days amivantamab-vmjw + lazertinib Sensitive : B J&J Press Release - 5 days - (New B)
ROS1 mutation	Non Small Cell Lung Cancer	ROS1 mutation	Non Small Cell Lung Cancer	crizotinib Sensitive: C4 – Case Studies J Med Case Rep - 5 days (New C4) crizotinib Sensitive : C4 J Med Case Rep - 5d	crizotinib Sensitive: C4 – Case Studies J Med Case Rep - 5 days crizotinib Sensitive : C4 J Med Case Rep - 5 days - (New C4)
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	aumolertinib Sensitive: B - Late Trials Front Oncol - 6 days (New C3) aumolertinib Sensitive : B Front Oncol - 6d	aumolertinib Sensitive: B - Late Trials Front Oncol - 6 days aumolertinib Sensitive : B Front Oncol - 6 days - (New C3)
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	nivolumab Sensitive: A1 - Approval Bristol-Myers Squibb Press Release - 1 week (New B) nivolumab Sensitive : A1 Bristol-Myers Squibb Press Release - 1wk	nivolumab Sensitive: A1 - Approval Bristol-Myers Squibb Press Release - 1 week nivolumab Sensitive : A1 Bristol-Myers Squibb Press Release - 1 week - (New B)
MET overexpression	Non Small Cell Lung Cancer	MET overexpression	Non Small Cell Lung Cancer	MYTX-011 Sensitive: B - Late Trials Businesswire - 1 week (New B) MYTX-011 Sensitive : B Businesswire - 1wk	MYTX-011 Sensitive: B - Late Trials Businesswire - 1 week MYTX-011 Sensitive : B Businesswire - 1 week - (New B)
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	afatinib Sensitive: A1 - Approval Thorac Cancer - 1 week (New C3) afatinib Sensitive : A1 Thorac Cancer - 1wk	afatinib Sensitive: A1 - Approval Thorac Cancer - 1 week afatinib Sensitive : A1 Thorac Cancer - 1 week - (New C3)
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	afatinib Sensitive: A1 - Approval Thorac Cancer - 1 week (New C3) afatinib Sensitive : A1 Thorac Cancer - 1wk	afatinib Sensitive: A1 - Approval Thorac Cancer - 1 week afatinib Sensitive : A1 Thorac Cancer - 1 week - (New C3)
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	erlotinib Sensitive: A1 - Approval Thorac Cancer - 1 week (New C3) erlotinib Sensitive : A1 Thorac Cancer - 1wk	erlotinib Sensitive: A1 - Approval Thorac Cancer - 1 week erlotinib Sensitive : A1 Thorac Cancer - 1 week - (New C3)
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	icotinib Sensitive: B - Late Trials Authorea - 1 week (New C3) icotinib Sensitive : B Authorea - 1wk	icotinib Sensitive: B - Late Trials Authorea - 1 week icotinib Sensitive : B Authorea - 1 week - (New C3)
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	pyrotinib Sensitive: C2 – Inclusion Criteria Thorac Cancer - 1 week (New C3) pyrotinib Sensitive : C2 Thorac Cancer - 1wk	pyrotinib Sensitive: C2 – Inclusion Criteria Thorac Cancer - 1 week pyrotinib Sensitive : C2 Thorac Cancer - 1 week - (New C3)
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	c-MET inhibitor Sensitive: C3 – Early Trials JTO Clin Res Rep - 1 week (New C3) c-MET inhibitor Sensitive : C3 JTO Clin Res Rep - 1wk	c-MET inhibitor Sensitive: C3 – Early Trials JTO Clin Res Rep - 1 week c-MET inhibitor Sensitive : C3 JTO Clin Res Rep - 1 week - (New C3)
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	AZD3759 Sensitive: C3 – Early Trials EClinicalMedicine - 1 week (New C3) AZD3759 Sensitive : C3 EClinicalMedicine - 1wk	AZD3759 Sensitive: C3 – Early Trials EClinicalMedicine - 1 week AZD3759 Sensitive : C3 EClinicalMedicine - 1 week - (New C3)
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	AZD3759 Sensitive: C3 – Early Trials EClinicalMedicine - 1 week (New C3) AZD3759 Sensitive : C3 EClinicalMedicine - 1wk	AZD3759 Sensitive: C3 – Early Trials EClinicalMedicine - 1 week AZD3759 Sensitive : C3 EClinicalMedicine - 1 week - (New C3)
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	PD1 inhibitor Sensitive: C3 – Early Trials JTO Clin Res Rep - 1 week (New C3) PD1 inhibitor Sensitive : C3 JTO Clin Res Rep - 1wk	PD1 inhibitor Sensitive: C3 – Early Trials JTO Clin Res Rep - 1 week PD1 inhibitor Sensitive : C3 JTO Clin Res Rep - 1 week - (New C3)
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	aglatimagene besadenovec Sensitive: C3 – Early Trials BioSpace - 1 week (New C3) aglatimagene besadenovec Sensitive : C3 BioSpace - 1wk	aglatimagene besadenovec Sensitive: C3 – Early Trials BioSpace - 1 week aglatimagene besadenovec Sensitive : C3 BioSpace - 1 week - (New C3)
PD-L1 underexpression	Non Small Cell Lung Cancer	PD-L1 underexpression	Non Small Cell Lung Cancer	aglatimagene besadenovec Sensitive: C3 – Early Trials BioSpace - 1 week (New C3) aglatimagene besadenovec Sensitive : C3 BioSpace - 1wk	aglatimagene besadenovec Sensitive: C3 – Early Trials BioSpace - 1 week aglatimagene besadenovec Sensitive : C3 BioSpace - 1 week - (New C3)
IDO1 overexpression	Non Small Cell Lung Cancer	IDO1 overexpression	Non Small Cell Lung Cancer	PD-L1 inhibitor Sensitive: C3 – Early Trials Clin Cancer Res - 1 week (New C3) PD-L1 inhibitor Sensitive : C3 Clin Cancer Res - 1wk	PD-L1 inhibitor Sensitive: C3 – Early Trials Clin Cancer Res - 1 week PD-L1 inhibitor Sensitive : C3 Clin Cancer Res - 1 week - (New C3)
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	pembrolizumab Sensitive: A1 - Approval Merck (MSD) Press Release - 2 weeks (New B) pembrolizumab Sensitive : A1 Merck (MSD) Press Release - 2wk	pembrolizumab Sensitive: A1 - Approval Merck (MSD) Press Release - 2 weeks pembrolizumab Sensitive : A1 Merck (MSD) Press Release - 2 weeks - (New B)
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	EGFR inhibitor Sensitive: A2 - Guideline J Neurooncol - 2 weeks (New C3) EGFR inhibitor Sensitive : A2 J Neurooncol - 2wk	EGFR inhibitor Sensitive: A2 - Guideline J Neurooncol - 2 weeks EGFR inhibitor Sensitive : A2 J Neurooncol - 2 weeks - (New C3)
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	afatinib Sensitive: A1 - Approval Thorac Cancer - 2 weeks (New C3) afatinib Sensitive : A1 Thorac Cancer - 2wk	afatinib Sensitive: A1 - Approval Thorac Cancer - 2 weeks afatinib Sensitive : A1 Thorac Cancer - 2 weeks - (New C3)
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval Daiichi Sankyo Press Release - 2 weeks (New C3) fam-trastuzumab deruxtecan-nxki Sensitive : A1 Daiichi Sankyo Press Release - 2wk	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval Daiichi Sankyo Press Release - 2 weeks fam-trastuzumab deruxtecan-nxki Sensitive : A1 Daiichi Sankyo Press Release - 2 weeks - (New C3)
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	amivantamab-vmjw Sensitive: B - Late Trials Nat Med - 2 weeks (New C3) amivantamab-vmjw Sensitive : B Nat Med - 2wk	amivantamab-vmjw Sensitive: B - Late Trials Nat Med - 2 weeks amivantamab-vmjw Sensitive : B Nat Med - 2 weeks - (New C3)
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	amivantamab-vmjw + lazertinib Sensitive: B - Late Trials Nat Med - 2 weeks (New C3) amivantamab-vmjw + lazertinib Sensitive : B Nat Med - 2wk	amivantamab-vmjw + lazertinib Sensitive: B - Late Trials Nat Med - 2 weeks amivantamab-vmjw + lazertinib Sensitive : B Nat Med - 2 weeks - (New C3)
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	anlotinib + sintilimab Sensitive: C2 – Inclusion Criteria Cancer Med - 2 weeks (New C3) anlotinib + sintilimab Sensitive : C2 Cancer Med - 2wk	anlotinib + sintilimab Sensitive: C2 – Inclusion Criteria Cancer Med - 2 weeks anlotinib + sintilimab Sensitive : C2 Cancer Med - 2 weeks - (New C3)
EGFR A763_Y764insFQEA	Non Small Cell Lung Cancer	EGFR A763_Y764insFQEA	Non Small Cell Lung Cancer	dacomitinib Sensitive: C3 – Early Trials Transl Cancer Res - 2 weeks (New C3) dacomitinib Sensitive : C3 Transl Cancer Res - 2wk	dacomitinib Sensitive: C3 – Early Trials Transl Cancer Res - 2 weeks dacomitinib Sensitive : C3 Transl Cancer Res - 2 weeks - (New C3)
HER-2 M774delinsWLV	Non Small Cell Lung Cancer	HER-2 M774delinsWLV	Non Small Cell Lung Cancer	dacomitinib Sensitive: C3 – Early Trials Transl Cancer Res - 2 weeks (New C3) dacomitinib Sensitive : C3 Transl Cancer Res - 2wk	dacomitinib Sensitive: C3 – Early Trials Transl Cancer Res - 2 weeks dacomitinib Sensitive : C3 Transl Cancer Res - 2 weeks - (New C3)
EGFR D770 delinsGY	Non Small Cell Lung Cancer	EGFR D770 delinsGY	Non Small Cell Lung Cancer	dacomitinib Sensitive: C3 – Early Trials Transl Cancer Res - 2 weeks (New C3) dacomitinib Sensitive : C3 Transl Cancer Res - 2wk	dacomitinib Sensitive: C3 – Early Trials Transl Cancer Res - 2 weeks dacomitinib Sensitive : C3 Transl Cancer Res - 2 weeks - (New C3)
EGFR exon 18 deletion	Non Small Cell Lung Cancer	EGFR exon 18 deletion	Non Small Cell Lung Cancer	dacomitinib Sensitive: C3 – Early Trials Transl Cancer Res - 2 weeks (New C3) dacomitinib Sensitive : C3 Transl Cancer Res - 2wk	dacomitinib Sensitive: C3 – Early Trials Transl Cancer Res - 2 weeks dacomitinib Sensitive : C3 Transl Cancer Res - 2 weeks - (New C3)
EGFR L747P	Non Small Cell Lung Cancer	EGFR L747P	Non Small Cell Lung Cancer	dacomitinib Sensitive: C3 – Early Trials Transl Cancer Res - 2 weeks (New C3) dacomitinib Sensitive : C3 Transl Cancer Res - 2wk	dacomitinib Sensitive: C3 – Early Trials Transl Cancer Res - 2 weeks dacomitinib Sensitive : C3 Transl Cancer Res - 2 weeks - (New C3)
EGFR wild-type + Chr 11p11.11-q12.1	Non Small Cell Lung Cancer	EGFR wild-type + Chr 11p11.11-q12.1	Non Small Cell Lung Cancer	EGFR inhibitor Sensitive: C3 – Early Trials Pharmgenomics Pers Med - 2 weeks (New C3) EGFR inhibitor Sensitive : C3 Pharmgenomics Pers Med - 2wk	EGFR inhibitor Sensitive: C3 – Early Trials Pharmgenomics Pers Med - 2 weeks EGFR inhibitor Sensitive : C3 Pharmgenomics Pers Med - 2 weeks - (New C3)
EGFR wild-type + Chr 9q21.31-q22.2	Non Small Cell Lung Cancer	EGFR wild-type + Chr 9q21.31-q22.2	Non Small Cell Lung Cancer	EGFR inhibitor Sensitive: C3 – Early Trials Pharmgenomics Pers Med - 2 weeks (New C3) EGFR inhibitor Sensitive : C3 Pharmgenomics Pers Med - 2wk	EGFR inhibitor Sensitive: C3 – Early Trials Pharmgenomics Pers Med - 2 weeks EGFR inhibitor Sensitive : C3 Pharmgenomics Pers Med - 2 weeks - (New C3)
EGFR wild-type + Chr 7q31.1-q31.31	Non Small Cell Lung Cancer	EGFR wild-type + Chr 7q31.1-q31.31	Non Small Cell Lung Cancer	EGFR inhibitor Sensitive: C3 – Early Trials Pharmgenomics Pers Med - 2 weeks (New C3) EGFR inhibitor Sensitive : C3 Pharmgenomics Pers Med - 2wk	EGFR inhibitor Sensitive: C3 – Early Trials Pharmgenomics Pers Med - 2 weeks EGFR inhibitor Sensitive : C3 Pharmgenomics Pers Med - 2 weeks - (New C3)
EGFR mutation + Chr 14q31.1-q31.3	Non Small Cell Lung Cancer	EGFR mutation + Chr 14q31.1-q31.3	Non Small Cell Lung Cancer	EGFR inhibitor Sensitive: C3 – Early Trials Pharmgenomics Pers Med - 2 weeks (New C3) EGFR inhibitor Sensitive : C3 Pharmgenomics Pers Med - 2wk	EGFR inhibitor Sensitive: C3 – Early Trials Pharmgenomics Pers Med - 2 weeks EGFR inhibitor Sensitive : C3 Pharmgenomics Pers Med - 2 weeks - (New C3)
EGFR mutation + Chr 1p13.3-p13.1	Non Small Cell Lung Cancer	EGFR mutation + Chr 1p13.3-p13.1	Non Small Cell Lung Cancer	EGFR inhibitor Resistant: C3 – Early Trials Pharmgenomics Pers Med - 2 weeks (New C3) EGFR inhibitor Resistant : C3 Pharmgenomics Pers Med - 2wk	EGFR inhibitor Resistant: C3 – Early Trials Pharmgenomics Pers Med - 2 weeks EGFR inhibitor Resistant : C3 Pharmgenomics Pers Med - 2 weeks - (New C3)
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	sotorasib + KPT-9274 Sensitive: D – Preclinical Mol Cancer Ther - 2 weeks (New D) sotorasib + KPT-9274 Sensitive : D Mol Cancer Ther - 2wk	sotorasib + KPT-9274 Sensitive: D – Preclinical Mol Cancer Ther - 2 weeks sotorasib + KPT-9274 Sensitive : D Mol Cancer Ther - 2 weeks - (New D)
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	gilteritinib Sensitive: D – Preclinical Cancer Sci - 2 weeks (New D) gilteritinib Sensitive : D Cancer Sci - 2wk	gilteritinib Sensitive: D – Preclinical Cancer Sci - 2 weeks gilteritinib Sensitive : D Cancer Sci - 2 weeks - (New D)
HLA-A2 positive	Non Small Cell Lung Cancer	HLA-A2 positive	Non Small Cell Lung Cancer	OSE 2101 Sensitive: B - Late Trials Ann Oncol - 3 weeks (New B) OSE 2101 Sensitive : B Ann Oncol - 3wk	OSE 2101 Sensitive: B - Late Trials Ann Oncol - 3 weeks OSE 2101 Sensitive : B Ann Oncol - 3 weeks - (New B)
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	sotorasib Sensitive: A1 - Approval Nihon Yakurigaku Zasshi - 3 weeks (New C3) sotorasib Sensitive : A1 Nihon Yakurigaku Zasshi - 3wk	sotorasib Sensitive: A1 - Approval Nihon Yakurigaku Zasshi - 3 weeks sotorasib Sensitive : A1 Nihon Yakurigaku Zasshi - 3 weeks - (New C3)
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	durvalumab Sensitive: A1 - Approval JAMA Oncol - 3 weeks (New C3) durvalumab Sensitive : A1 JAMA Oncol - 3wk	durvalumab Sensitive: A1 - Approval JAMA Oncol - 3 weeks durvalumab Sensitive : A1 JAMA Oncol - 3 weeks - (New C3)
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	amivantamab-vmjw Sensitive: B - Late Trials J&J Press Release - 3 weeks (New B) amivantamab-vmjw Sensitive : B J&J Press Release - 3wk	amivantamab-vmjw Sensitive: B - Late Trials J&J Press Release - 3 weeks amivantamab-vmjw Sensitive : B J&J Press Release - 3 weeks - (New B)
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	amivantamab-vmjw + lazertinib Sensitive: B - Late Trials J&J Press Release - 3 weeks (New B) amivantamab-vmjw + lazertinib Sensitive : B J&J Press Release - 3wk	amivantamab-vmjw + lazertinib Sensitive: B - Late Trials J&J Press Release - 3 weeks amivantamab-vmjw + lazertinib Sensitive : B J&J Press Release - 3 weeks - (New B)
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	lazertinib Sensitive: B - Late Trials J Thorac Oncol - 3 weeks (New B) lazertinib Sensitive : B J Thorac Oncol - 3wk	lazertinib Sensitive: B - Late Trials J Thorac Oncol - 3 weeks lazertinib Sensitive : B J Thorac Oncol - 3 weeks - (New B)
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	lazertinib Sensitive: B - Late Trials J Thorac Oncol - 3 weeks (New B) lazertinib Sensitive : B J Thorac Oncol - 3wk	lazertinib Sensitive: B - Late Trials J Thorac Oncol - 3 weeks lazertinib Sensitive : B J Thorac Oncol - 3 weeks - (New B)
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	U3-1402 Sensitive: C2 – Inclusion Criteria J Clin Oncol - 3 weeks (New C3) U3-1402 Sensitive : C2 J Clin Oncol - 3wk	U3-1402 Sensitive: C2 – Inclusion Criteria J Clin Oncol - 3 weeks U3-1402 Sensitive : C2 J Clin Oncol - 3 weeks - (New C3)
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	U3-1402 Sensitive: C2 – Inclusion Criteria J Clin Oncol - 3 weeks (New C3) U3-1402 Sensitive : C2 J Clin Oncol - 3wk	U3-1402 Sensitive: C2 – Inclusion Criteria J Clin Oncol - 3 weeks U3-1402 Sensitive : C2 J Clin Oncol - 3 weeks - (New C3)
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	anlotinib Sensitive: C2 – Inclusion Criteria Int J Gen Med - 3 weeks (New C3) anlotinib Sensitive : C2 Int J Gen Med - 3wk	anlotinib Sensitive: C2 – Inclusion Criteria Int J Gen Med - 3 weeks anlotinib Sensitive : C2 Int J Gen Med - 3 weeks - (New C3)
EGFR mutation	Lung Adenocarcinoma	EGFR mutation	Lung Adenocarcinoma	EGFR inhibitor Sensitive: C3 – Early Trials BMC Cancer - 3 weeks (New C3) EGFR inhibitor Sensitive : C3 BMC Cancer - 3wk	EGFR inhibitor Sensitive: C3 – Early Trials BMC Cancer - 3 weeks EGFR inhibitor Sensitive : C3 BMC Cancer - 3 weeks - (New C3)
TFRC overexpression + PD-L1 underexpression	Non Small Cell Lung Cancer	TFRC overexpression + PD-L1 underexpression	Non Small Cell Lung Cancer	nivolumab Sensitive: C3 – Early Trials Cancers (Basel) - 3 weeks (New C3) nivolumab Sensitive : C3 Cancers (Basel) - 3wk	nivolumab Sensitive: C3 – Early Trials Cancers (Basel) - 3 weeks nivolumab Sensitive : C3 Cancers (Basel) - 3 weeks - (New C3)
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	lorlatinib Sensitive: A1 - Approval lorlatinib Sensitive : A1	lorlatinib Sensitive: A1 - Approval lorlatinib Sensitive : A1
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	alectinib Sensitive: A1 - Approval alectinib Sensitive : A1	alectinib Sensitive: A1 - Approval alectinib Sensitive : A1
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
ALK fusion	Non Small Cell Lung Cancer	ALK fusion	Non Small Cell Lung Cancer	brigatinib Sensitive: A1 - Approval brigatinib Sensitive : A1	brigatinib Sensitive: A1 - Approval brigatinib Sensitive : A1
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	brigatinib Sensitive: A1 - Approval brigatinib Sensitive : A1	brigatinib Sensitive: A1 - Approval brigatinib Sensitive : A1
ROS1 fusion	Non Small Cell Lung Cancer	ROS1 fusion	Non Small Cell Lung Cancer	entrectinib Sensitive: A1 - Approval entrectinib Sensitive : A1	entrectinib Sensitive: A1 - Approval entrectinib Sensitive : A1
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	tepotinib Sensitive: A1 - Approval tepotinib Sensitive : A1	tepotinib Sensitive: A1 - Approval tepotinib Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	dacomitinib Sensitive: A1 - Approval dacomitinib Sensitive : A1	dacomitinib Sensitive: A1 - Approval dacomitinib Sensitive : A1
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	lazertinib Sensitive: A1 - Approval lazertinib Sensitive : A1	lazertinib Sensitive: A1 - Approval lazertinib Sensitive : A1
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	dacomitinib Sensitive: A1 - Approval dacomitinib Sensitive : A1	dacomitinib Sensitive: A1 - Approval dacomitinib Sensitive : A1
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	capmatinib Sensitive: A1 - Approval capmatinib Sensitive : A1	capmatinib Sensitive: A1 - Approval capmatinib Sensitive : A1
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	cemiplimab-rwlc Sensitive: A1 - Approval cemiplimab-rwlc Sensitive : A1	cemiplimab-rwlc Sensitive: A1 - Approval cemiplimab-rwlc Sensitive : A1
RET fusion	Non Small Cell Lung Cancer	RET fusion	Non Small Cell Lung Cancer	pralsetinib Sensitive: A1 - Approval pralsetinib Sensitive : A1	pralsetinib Sensitive: A1 - Approval pralsetinib Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	cisplatin + pemetrexed Sensitive: A1 - Approval cisplatin + pemetrexed Sensitive : A1	cisplatin + pemetrexed Sensitive: A1 - Approval cisplatin + pemetrexed Sensitive : A1
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	pemetrexed Sensitive: A1 - Approval pemetrexed Sensitive : A1	pemetrexed Sensitive: A1 - Approval pemetrexed Sensitive : A1
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	cisplatin Sensitive: A1 - Approval cisplatin Sensitive : A1	cisplatin Sensitive: A1 - Approval cisplatin Sensitive : A1
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	crizotinib Sensitive: A1 - Approval crizotinib Sensitive : A1	crizotinib Sensitive: A1 - Approval crizotinib Sensitive : A1
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	crizotinib Sensitive: A1 - Approval crizotinib Sensitive : A1	crizotinib Sensitive: A1 - Approval crizotinib Sensitive : A1

Non Small Cell Lung Cancer

Associations(3548)

Associations
(3548)